@article {7767,
	title = {Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma},
	journal = {Leukemia Research},
	volume = {34},
	year = {2010},
	note = {Cited By :36Export Date: 21 February 2017},
	month = {2010},
	pages = {1111 - 1118},
	abstract = {Multiple myeloma (MM) is an incurable disease characterized by the accumulation of malignant plasma cells in the bone marrow. Recently, an improved understanding of the biology of the disease has led to the development of targeted agents such as the proteasome inhibitor bortezomib and the immunomodulatory agents thalidomide and lenalidomide; however, MM remains incurable. The combination of bortezomib and an HDAC inhibitor synergistically induces MM cell apoptosis and may be of value in the treatment of patients with relapsed/refractory MM. This review examines the potential of combined proteasome and HDAC inhibition in the treatment of relapsed/refractory MM. {\textcopyright} 2010.},
	keywords = {bortezomib, Histone deacetylase inhibitor, multiple myeloma, proteasome inhibitor, Vorinostat},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955270038\&doi=10.1016\%2fj.leukres.2010.04.001\&partnerID=40\&md5=784e9368f67b34d24d79c97fa9938b61},
	author = {Jagannath, S. and Dimopoulos, M.A. and Lonial, S.}
}
